Drug tendering: drug supply and shortage implications for the uptake of biosimilars
Authors:
Open Access
- 1 September 2017
- journal article
- review article
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 9, 573-584
Abstract
Due to the continued increase in global spending on health care, payers have introduced a number of programs, policies, and agreements on pharmaceutical pricing in order to control costs. While incentives to increase generic drug use have achieved significant savings, other cost-containment measures are required. Tendering is a formal procedure to purchase medications using competitive bidding for a particular contract. Although useful for cost containment, tendering can lead to decreased competition in a given market. Consequently, drug shortages can occur, resulting in changes to treatment plans to products that may have lower efficacy and/or an increased risk of adverse effects. Therefore, care must be taken to ensure that tendering does not negatively impact patient care or the health care system. A large and expanding portion of total pharmaceutical expenditure is for biologic therapies. These agents have revolutionized the treatment of many diseases, including cancer and inflammatory conditions; however, patient access to biologic drugs can be limited due to availability, insurance coverage, and cost. As branded biologic therapies reach the end of patent- and data-protection periods, biosimilars are being approved as lower-cost alternatives. Biosimilars are products that are highly similar to the originator product with no clinically meaningful differences in terms of safety, purity, or potency. As more biosimilars receive regulatory approval and adoption increases, these therapies are expected to have an impact on global health care spending and should result in overall savings. However, the use of tendering to maximize the potential benefits of biosimilars has varied across the world. Therefore, the objectives of this review are to examine the drug-tendering process and its implications on drug supply and drug shortages, as well as to describe biosimilars and how tendering may influence their uptake.Keywords
This publication has 39 references indexed in Scilit:
- Biosimilars in IBD: from theory to practiceNature Reviews Gastroenterology & Hepatology, 2016
- Development of biosimilars in an era of oncologic drug shortagesDrug Design, Development and Therapy, 2015
- Equitable Prices of Single-Source Drugs in ThailandApplied Health Economics and Health Policy, 2015
- Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging MarketsPharmaceuticals, 2014
- Critical Drug Shortages: Implications for Emergency MedicineAcademic Emergency Medicine, 2014
- Drug Shortages: A Complex Health Care CrisisMayo Clinic Proceedings, 2014
- Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 2013
- The State of the Art in the Development of BiosimilarsClinical Pharmacology & Therapeutics, 2012
- The drug shortage crisis in the United States: causes, impact, and management strategies.2011
- Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?Health Policy, 2011